Where to Buy BPC-157 in 2026: A Honest Guide
The landscape has changed. Peptide Sciences is gone, reclassification is pending, and the grey market is shrinking. Here's what's left.
BPC-157 is not FDA-approved. It has zero completed human clinical trials. It is currently classified as Category 2 by the FDA, meaning it cannot be legally compounded by licensed pharmacies. A reclassification to Category 1 has been announced but not yet formalized. Grey-market BPC-157 labeled “for research use only” exists in a legal grey area that is narrowing rapidly. PeptideExaminer does not endorse the use of grey-market peptides. This guide provides information for readers making their own informed decisions.
The Landscape Has Changed
If you’re looking for BPC-157 in March 2026, the market looks nothing like it did six months ago.
Peptide Sciences — gone. The largest and highest-rated grey-market vendor shut down on March 6, 2026. Their BPC-157 had a Finnrick A rating. That option no longer exists.
Amino Asylum — gone. FDA raided their warehouse in June 2025. Website offline since.
At least 8 vendors have shut down or been shut down between 2025 and early 2026.
The FDA reclassification that would restore legal compounding access has been announced but not published — 29 days and counting.
What remains are a shrinking number of grey-market vendors, emerging telehealth platforms, and the pending promise of licensed compounding pharmacies. Here’s the honest assessment of each pathway.
Option 1: Remaining Grey-Market Vendors
These vendors sell BPC-157 as a “research chemical.” The products are not FDA-approved, not pharmaceutical-grade, and not legally intended for human use. That said, some have meaningful quality differentiation.
Vendors with Independent Testing Data
Eternal Peptides — Grade: B Finnrick A rating on BPC-157 (7 samples, May-Nov 2025). One of only two vendors with a confident Finnrick A for BPC-157. Public lab test archive on website. Premium pricing. Newer vendor with limited review history.
Peptide Partners — Referenced in Finnrick database Finnrick A rating on BPC-157 alongside Peptide Sciences and Eternal Peptides. Limited vendor profile data available.
Vendors Without Independent BPC-157 Testing
Paradigm Peptides — Grade: C+ Decade of operations, BBB A+ rated. Finnrick tested retatrutide (A) but no independent BPC-157 testing data. Claims 98%+ purity without public COAs. Mixed reputation including one adulteration allegation.
Strate Labs — Grade: D+ Over a decade of operations but ITC Cease and Desist Order for tirzepatide importation. No Finnrick BPC-157 data. TikTok influencer marketing raises credibility concerns. Reasonable for non-GLP-1 products but compliance issues are serious.
Prime Peptides — Grade: C- FDA warning letter (December 2024). COAs available but lot number matching inconsistent. No Finnrick data. Responsive customer service is a genuine positive, but the warning letter is a significant mark.
What to Look For
If you’re purchasing grey-market BPC-157, prioritize these signals in order:
Finnrick or Janoshik independent testing is the strongest quality indicator. Vendor-provided COAs are better than nothing but can be fabricated.
Batch-specific COAs with QR verification that link to a laboratory database. Generic COAs or COAs reused across batches are red flags.
Credit card payment accepted signals that a payment processor has done basic vetting. Vendors limited to cryptocurrency, Venmo, or Zelle have been rejected by processors — that’s a meaningful negative signal.
US-based operations with verifiable address provide at least some accountability framework.
Option 2: Compounding Pharmacies (Pending Reclassification)
Current status: BPC-157 is Category 2 — compounding is prohibited. If the FDA formally reclassifies BPC-157 to Category 1, licensed 503A pharmacies will be able to compound it with a valid physician prescription.
What you’ll need: A physician willing to prescribe BPC-157. A licensed compounding pharmacy with appropriate quality controls (USP 795/797 compliance). Pharmaceutical-grade API sourcing.
Expected pricing: $150-300/month based on historical compounding pharmacy pricing for similar peptides.
Advantages over grey-market: Pharmaceutical-grade APIs, sterility testing, endotoxin testing, physician oversight, legal protection, batch consistency, and adverse event monitoring.
Timeline: Unknown. The reclassification was announced February 27. As of March 28, no formal FDA action has been published. When it happens, we’ll update this guide immediately.
Option 3: Oral BPC-157 Supplements
Several companies sell oral BPC-157 in capsule form, positioned as dietary supplements. The regulatory status of these products is ambiguous — legal experts note that BPC-157 is a synthetic peptide with no dietary supplement status under DSHEA, and no New Dietary Ingredient Notification has been filed.
That said, the FDA has not pursued enforcement against oral BPC-157 sellers at scale.
For oral BPC-157, the critical question is bioavailability. We’ve covered this extensively in our oral peptide bioavailability guide. The short version: oral BPC-157 likely has meaningful local (gut) effects based on its mechanism of action, but systemic bioavailability for reaching injuries outside the GI tract is unproven.
Integrative Peptides — Physician-founded, oral capsule format. No public COAs. Mixed independent verification.
Infiniwell — SNAC-enhanced oral BPC-157 (BPC Rapid Pro). SNAC technology is real for semaglutide but unproven for BPC-157 specifically. Premium pricing ($159.95/60 caps).
Option 4: Telehealth Platforms (Emerging)
Hims & Hers — Grade: B+. Building peptide manufacturing in California. Peptide product line confirmed on Q4 2025 earnings call. Not yet launched. When available, this will be a physician-supervised, quality-controlled, legal pathway.
Other telehealth platforms: Multiple smaller telehealth companies have announced or are developing peptide programs in anticipation of reclassification. Quality and legitimacy vary significantly.
The Evidence Reminder
Before spending money on BPC-157 from any source, here’s what the research actually shows:
Animal studies: Extensive and consistently positive across multiple tissue types. But nearly all come from a single research group (Predrag Sikiric’s lab in Croatia), which has published over 150 papers on BPC-157. Independent replication is minimal.
Human studies: Zero completed clinical trials. One retrospective case series for knee pain. That’s it.
STAT News investigation (February 2026): Documented that 35 of 36 published BPC-157 studies are animal-only from the single Croatian lab with undisclosed conflicts of interest.
This doesn’t mean BPC-157 doesn’t work. It means the evidence base is far thinner than marketing suggests. Legal access through compounding won’t change the evidence — it will change the quality, safety, and accountability of the product.
This guide will be updated when the FDA publishes formal reclassification guidance. Bookmark and check back.
PeptideExaminer — We don’t sell peptides. We tell you the truth about them.